A Phase I study of AT-101 with Cisplatin and Etoposide in patients with advanced solid tumors with an Expanded Cohort in Extensive-Stage Small Cell Lung Cancer

BACKGROUND: A phase I, dose-escalation study of AT-101 with cisplatin and etoposide was conducted to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety and pharmacokinetics in patients with advanced solid tumors, with an expanded cohort in patients with extensive-stag...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Schelman, William R., Mohammed, Tabraiz A., Traynor, Anne M., Kolesar, Jill M., Marnocha, Rebecca M., Eickhoff, Jens, Keppen, Michael, Alberti, Dona B., Wilding, George, Takebe, Naoko, Liu, Glenn
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3895103/
https://ncbi.nlm.nih.gov/pubmed/23860642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9999-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars